Mark Phillips
Compliance Officer bei COGNETIVITY NEUROSCIENCES LTD.
Vermögen: 10 607 $ am 30.04.2024
Profil
Mark A.
Phillips is currently the Chairman at Cognetivity Ltd., Director & Chief Compliance Officer at Cognetivity Neurosciences Ltd., Non-Executive Director at Fluorogenics Ltd., and Director at Centillion Technology Ltd.
He previously worked as Senior Vice President-Research & Development at GSK Plc.
Phillips holds a doctorate degree from the University of Cambridge and an undergraduate degree from Loughborough University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.11.2022 | 815 934 ( 0,91% ) | 10 607 $ | 30.04.2024 |
Aktive Positionen von Mark Phillips
| Unternehmen | Position | Beginn |
|---|---|---|
| COGNETIVITY NEUROSCIENCES LTD. | Compliance Officer | 21.12.2017 |
Cognetivity Ltd.
 Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Vorsitzender | 01.01.2014 |
Fluorogenics Ltd.
 Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Direktor/Vorstandsmitglied | 01.09.2016 |
| Centillion Technology Ltd. | Direktor/Vorstandsmitglied | 01.01.2021 |
Ehemalige bekannte Positionen von Mark Phillips
| Unternehmen | Position | Ende |
|---|---|---|
| GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark Phillips
| University of Cambridge | Doctorate Degree |
| Loughborough University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| COGNETIVITY NEUROSCIENCES LTD. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cognetivity Ltd.
Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Health Technology |
Fluorogenics Ltd.
Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Commercial Services |
| Centillion Technology Ltd. |
